Effectiveness of antiretroviral therapy in individuals who for economic reasons were switched from a once-daily single-tablet regimen to a triple-tablet regimen

Journal of Acquired Immune Deficiency Syndromes

Volumn 66, Issue 4, 2014, Pages 407-413

  Engsig, Frederik N ^a,b   Gerstoft, Jan ^a   Helleberg, Marie ^a   Nielsen, Lars N ^c   Kronborg, Gitte ^c   Mathiesen, Lars R ^c   Obel, Niels ^a  

^a University of Copenhagen   (Denmark)

^b STATENS SERUM INSTITUT   (Denmark)

^c Mental Health Center Glostrup   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; GENERIC DRUG; LAMIVUDINE; TENOFOVIR; VIRUS RNA;

ADULT; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ASSESSMENT; COHORT ANALYSIS; COMBINATION ANTIRETROVIRAL THERAPY; CONFIDENCE INTERVAL; DENMARK; DRUG EFFICACY; DRUG MIXTURE; DRUG SUBSTITUTION; ECONOMIC ASPECT; FEMALE; HEALTH CARE SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VIRUS MUTATION; VIRUS RESISTANCE;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DENMARK; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84903698434     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000199     Document Type: Article

References (31)

1. Holmes WC, Bilker WB, Wang H, et al. HIV/AIDS-specific quality of life and adherence to antiretroviral therapy over time. J Acquir Immune Defic Syndr. 2007;46:323-327. (Pubitemid 350287360)
2. Pozniak AL, Gallant JE, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes-a 96-week analysis. J Acquir Immune Defic Syndr. 2006;43:535-540. (Pubitemid 44885619)
3. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354:251-260. (Pubitemid 43113030)
4. FDA approval of Atripla, 3-drug fixed dose combination antiretroviral. Available at: http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/ HIVandAIDSActivties/uc m12444 4.htm. Accessed November 1, 2013
5. European commision approves Atripla (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the first once-daily single tablet regimen for virologically suppressed adults with HIV-1 infection. Available at: http://www.natap.org/2007/HIV/121707-04.htm. Accessed November 1, 2013
6. Consolidating guidelines on the use of antiretroviral drugs for treating and prevententing HIV infection. Recommendations for a public health approach. 2013. Available at: http://apps.who.int/iris/bitstream/10665/85321/1/ 9789241505727-eng.pdf?ua=1. Accessed November 1, 2013
7. Antiviral behandling af HIV-smittede. 2013. Available at: http://www.infmed.dk/guidelines#antiviralbehandling-hiv-2013.pdf. Accessed April 1, 2014
8. Walensky RP, Sax PE, Nakamura YM, et al. Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med. 2013;158:84-92
9. Bangsberg DR, Ragland K, Monk A, et al. A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people. AIDS. 2010;24:2835-2840
10. Cohen CJ, Meyers JL, Davis KL. Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US medicaid population with HIV. BMJ Open. 2013;3:e003028
11. Sax PE, Meyers JL, Mugavero M, et al. Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States. PLoS One. 2012;7:31591
12. Nachega JB, Parienti JJ, Uthman OA, et al. Lower pill Burden and once-daily dosing antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized Controlled trials. Clin Infect Dis. 2014;58:1297-1307
13. Obel N, Engsig FN, Rasmussen LD, et al. Cohort profile: the Danish HIV cohort study. Int J Epidemiol. 2009;38:1202-1206
14. Audelin AM, Lohse N, Obel N, et al. The incidence rate of HIV type-1 drug resistance in patients on antiretroviral therapy: a nationwide population-based Danish cohort study 1999-2005. Antivir Ther. 2009;14: 995-1000
15. Bennett DE, Camacho RJ, Otelea D, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One. 2009;4:e4724
16. Region Hovedstadens Apotek. Klinisk framaceutisk service. 2013. Available at: www.apotek-regionh.dk. Accessed November 1, 2013
17. Jensen-Fangel S, Pedersen L, Pedersen C, et al. The effect of race/ethnicity on the outcome of highly active antiretroviral therapy for human immunodeficiency virus type 1-infected patients. Clin Infect Dis. 2002; 35:1541-1548. (Pubitemid 36024181)
18. Jason PF, Robert JG. A Proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-509
19. Shubber Z, Calmy A, Andrieux-Meyer I, et al. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. AIDS. 2013;27:1403-1412
20. Grennan JT, Loutfy MR, Su D, et al. Therapy: a systematic review and meta-analysis magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. J Infect Dis. 2012;205:1230-1238
21. Helleberg M, Högblom A, Sönderborg A, et al. HIV care in the Swedish- Danish HIV cohort 1995-2010: closing the Gaps. PLoS One. 2013;8: e72257
22. Thompson MA, Mugavero MJ, Amico KR, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med. 2012; 156:817-833
23. Hanna DB, Hessol NA, Golub ET, et al. Increase in single-tablet regimen use and associated improvements in adherence-related outcomes in HIVinfected women. J Acquir Immune Defic Syndr. 2014;65:587-596
24. Beck EJ, Mandalia S, Sangha R, et al. Lower healthcare costs associated with the use of a single-pill ARV regimen in the UK, 2004-2008. PLoS One. 2012;7:e47376
25. WHO. Pharmacological equivalence and clinical interchangeability of lamivudine and emtricitabine: a review of current literature. 2013. Available at: http://www.who.int/hiv/pub/treatment2/lamivudine-emtricibatine/en/. Accessed November 1, 2013
26. Benson CA, van der Horst C, Lamarca A, et al. A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV. AIDS. 2004;18:2269-2276. (Pubitemid 39620219)
27. Svicher V, Alteri C, Artese A, et al. Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovircontaining regimens. J Acquir Immune Defic Syndr. 2010;55:336-344
28. Marcelin AG, Charpentier C, Wirden M, et al. Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens. J Antimicrob Chemother. 2012;67:1475-1478
29. Rousseau FS, Wakeford C, Mommeja-Marin H, et al. Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients. J Infect Dis. 2003; 188:1652-1658. (Pubitemid 38010675)
30. McColl DJ, Margot N, Chen SS, et al. Reduced emergence of the M184V/I resistance mutation when antiretroviral-naive subjects use emtricitabine versus lamivudine in regimens composed of two NRTIs plus the NNRTI efavirenz. HIV Clin Trials. 2011;12:61-70
31. Deeks ED, Perry CM. Efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Atripla(R)): a review of its use in the management of HIV infection. Drugs. 2010;70:2315-2338